Jason Karlawish

speaker

1,378 appearances 5 recordings 1 series first heard Feb 2021 last heard Dec 2023

Jason Karlawish’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

No recordings in the last 12 months.Older appearances are listed below; set an alert to hear about the next one.

Appearances

newest first · ▶ plays the moment

GeriPal - A Geriatrics and Palliative Medicine Podcast · Redefining Alzheimer's Disease: A Podcast with Heather Whitson, Jason Karlawish, Lon Schneider · 1 Dec 2023 podcast

And I I think

We have to think a bit about the the the policy implications there that would flow from that new way of counting the disease.

But again, if you know, we could validate that some biomarker measure does quantify Alzheimer's disease independent of symptoms, and we may get there.

Yeah.

You know, that would be the way we would count the disease.

But then we're gonna have to also count the disease based on clinical severity to not lose sight of the fact that dementia matters and that's why we care about this disease.

If you didn't get dementia, it wouldn't be a problem.

so so let me I I I I hope that five, ten, I don't know how many years from now, this conversation will be viewed as very historical.

Because it was all about amyloid and five to ten years from now

We will have developed ways of measuring the brain that allow you to say whose brain.

is beginning to show showing signs of neuron dysfunction, neuron death.

And I think that's the exciting field that is unfolding.

Measures like neurofilament light, GFAP.

measures of neuroinflammation, neurodegeneration, some of which are agnostic to disease.

They just indicate whether neurons are dysfunctional or dying.

And so I would say to my colleagues on the listening and watching the few

Don't be cynical about biomarkers.

I think the one takeaway I wouldn't want people to have is these biomarkers are just the latest flagpole sitting.

This is the beginning of a new way of measuring and defining the brain in health and disease.

I think amyloid gets a lot of attention because it was one of the first markers to be developed and the work they did was beautiful and elegant.

Showing 161–180 of 1,378 · page 9 of 69